"FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose" (see https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use ).
The news release in part says the following.
"Today, the U.S. Food and Drug Administration amended the emergency use
authorizations (EUAs) of the Moderna COVID-19 Vaccine and the
Pfizer-BioNTech COVID-19 Vaccine to authorize bivalent formulations of
the vaccines for use as a single booster dose at least two months
following primary or booster vaccination. The bivalent vaccines, which
we will also refer to as “updated boosters,” contain two messenger RNA
(mRNA) components of SARS-CoV-2 virus, one of the original strain of
SARS-CoV-2 and the other one in common between the BA.4 and BA.5
lineages of the omicron variant of SARS-CoV-2.
... The BA.4 and BA.5 lineages of the omicron variant are currently causing
most cases of COVID-19 in the U.S. and are predicted to circulate this
fall and winter. In June, the agency’s Vaccines and Related Biological
Products Advisory Committee voted overwhelmingly to include an omicron
component in COVID-19 booster vaccines.
... Based on the data supporting each of these authorizations, the bivalent
COVID-19 vaccines are expected to provide increased protection against
the currently circulating omicron variant. Individuals who receive a
bivalent COVID-19 vaccine may experience side effects commonly reported
by individuals who receive authorized or approved monovalent mRNA
COVID-19 vaccines.
... After 28 days, the immune response against BA.1 of the participants
who received the bivalent vaccine was better than the immune response of
those who had received the monovalent Moderna COVID-19 Vaccine.
The safety of a single booster dose of the Moderna COVID-19 Vaccine,
Bivalent for individuals 18 years of age and older is supported by
safety data from a clinical study which evaluated a booster dose of
Moderna’s investigational bivalent COVID-19 vaccine (original and
omicron BA.1), safety data from clinical trials which evaluated primary
and booster vaccination with the monovalent Moderna COVID-19 Vaccine,
and postmarketing safety data with the monovalent Moderna COVID-19
Vaccine.
The safety data accrued with the bivalent vaccine (original and
omicron BA.1) and with the monovalent Moderna COVID-19 Vaccine are
relevant to the Moderna COVID-19 Vaccine, Bivalent because these
vaccines are manufactured using the same process.
... With today’s authorization, the FDA has also revised the EUA of the
Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine to
remove the use of the monovalent Moderna and Pfizer-BioNTech COVID-19
vaccines for booster administration for individuals 18 years of age and
older and 12 years of age and older, respectively. These monovalent
vaccines continue to be authorized for use for administration of a
primary series for individuals 6 months of age and older as described in
the letters of authorization. At this time, the Pfizer-BioNTech
COVID-19 Vaccine remains authorized for administration of a single
booster dose for individuals 5 through 11 years of age at least five
months after completing a primary series of the Pfizer-BioNTech COVID-19
Vaccine."
As a result of my reading the above, and noticing it meets my criteria which I stated in my prior post, I will probably get the Moderna Bivalent COVID-19 Vaccine as a single booster dose.